Adalimumab as a cause of kidney injury in patients with Crohn's disease.

Krzysztof SkoczyńskiJan KoziejSylwia SzymańskaŁukasz ObryckiRyszard GrendaMieczyslaw Litwin

Published in: Pediatric nephrology (Berlin, Germany) (2024)

Due to the risk of KI in patients undergoing ADM therapy, careful assessment of kidney function and early specialist referral are required. Timely withdrawal of ADM can significantly reduce kidney damage, but in some cases, the kidney damage can be irreversible.

Keyphrases

patients undergoing
oxidative stress
rheumatoid arthritis
palliative care
primary care
juvenile idiopathic arthritis
neoadjuvant chemotherapy
stem cells
squamous cell carcinoma
radiation therapy
systemic lupus erythematosus
hidradenitis suppurativa